Transfusion Medicine | GUIDELINES BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn

BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn.

Investigation of Paternal RhD Zygosity by Two Molecular Methods among Blood Donors in Kurdistan Province, Iran

Background: RhD antigen system is the leading cause of hemolytic disease of the fetus and newborn (HDFN). Paternal molecular RhD zygosity test is valuable to decide on the use of anti-D immunoglobulin prophylaxis in Rh D-negative pregnant women. We aimed to investigate the paternal RhD zygosity by two molecular methods among blood donors in Kurdistan province, the west of Iran. We also compared...

Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)

RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn (HDN) which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody ...

Prevalence and Haemolytic Significance of Red Cell Antibodies among Dangerous Universal Donors in a Tertiary Care Hospital in South India

Background and Aims: A subgroup of group O individuals called ‘dangerous universal donors’ have immune (IgG) anti A and anti B antibodies which are active at 37˚C and capable of reacting with the red cells and causing lysis. The aim of this study was to find the prevalence of dangerous O group among the voluntary donor population and to assess the relation between the degree of haemolysis and t...

Fetal RHD Genotyping Using Real-Time Polymerase Chain Reaction Analysis of Cell-Free Fetal DNA in Pregnancy of RhD Negative Women in South of Iran

Objective Maternal-fetal RhD antigen incompatibility causes approximately 50% of clinically significant alloimmunization cases. The routine use of prophylactic anti-D immunoglobulin has dramatically reduced hemolytic disease of the fetus and newborn. Recently, fetal RHD genotyping in RhD negative pregnant women has been suggested for appropriate use of anti-D immunoglobulin antenatal prophylaxi...